Logo image of HBP.CA

HELIX BIOPHARMA CORP (HBP.CA) Stock Fundamental Analysis

Canada - TSX:HBP - CA4229102088 - Common Stock

2.17 CAD
+0.04 (+1.88%)
Last: 10/29/2025, 7:00:00 PM
Fundamental Rating

0

Taking everything into account, HBP scores 0 out of 10 in our fundamental rating. HBP was compared to 21 industry peers in the Biotechnology industry. Both the profitability and financial health of HBP have multiple concerns. HBP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HBP has reported negative net income.
HBP had a negative operating cash flow in the past year.
HBP had negative earnings in each of the past 5 years.
In the past 5 years HBP always reported negative operating cash flow.
HBP.CA Yearly Net Income VS EBIT VS OCF VS FCFHBP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of HBP (-944.80%) is worse than 80.95% of its industry peers.
Industry RankSector Rank
ROA -944.8%
ROE N/A
ROIC N/A
ROA(3y)-469.8%
ROA(5y)-358.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HBP.CA Yearly ROA, ROE, ROICHBP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20K 40K 60K

1.3 Margins

HBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HBP.CA Yearly Profit, Operating, Gross MarginsHBP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

HBP has more shares outstanding than it did 1 year ago.
HBP has less shares outstanding than it did 5 years ago.
There is no outstanding debt for HBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HBP.CA Yearly Shares OutstandingHBP.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HBP.CA Yearly Total Debt VS Total AssetsHBP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -286.33, we must say that HBP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -286.33, HBP is not doing good in the industry: 80.95% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -286.33
ROIC/WACCN/A
WACCN/A
HBP.CA Yearly LT Debt VS Equity VS FCFHBP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

HBP has a Current Ratio of 0.42. This is a bad value and indicates that HBP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.42, HBP perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
A Quick Ratio of 0.42 indicates that HBP may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.42, HBP is in line with its industry, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.42
Quick Ratio 0.42
HBP.CA Yearly Current Assets VS Current LiabilitesHBP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

HBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.62%.
EPS 1Y (TTM)-76.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HBP.CA Yearly EPS VS EstimatesHBP.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HBP. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBP.CA Price Earnings VS Forward Price EarningsHBP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HBP.CA Per share dataHBP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

HBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HELIX BIOPHARMA CORP

TSX:HBP (10/29/2025, 7:00:00 PM)

2.17

+0.04 (+1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-22 2025-10-22
Earnings (Next)12-15 2025-12-15
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners7.71%
Ins Owner ChangeN/A
Market Cap165.74M
Revenue(TTM)N/A
Net Income(TTM)-9533000
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -944.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-469.8%
ROA(5y)-358.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.42
Quick Ratio 0.42
Altman-Z -286.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.32%
OCF growth 3YN/A
OCF growth 5YN/A

HELIX BIOPHARMA CORP / HBP.CA FAQ

Can you provide the ChartMill fundamental rating for HELIX BIOPHARMA CORP?

ChartMill assigns a fundamental rating of 0 / 10 to HBP.CA.


Can you provide the valuation status for HELIX BIOPHARMA CORP?

ChartMill assigns a valuation rating of 0 / 10 to HELIX BIOPHARMA CORP (HBP.CA). This can be considered as Overvalued.


What is the profitability of HBP stock?

HELIX BIOPHARMA CORP (HBP.CA) has a profitability rating of 0 / 10.